Current status of silica-based nanoparticles as therapeutics and its potential as therapies against viruses.

ABSTRACT: In the past decade, interest in nanoparticles for clinical indications has been steadily gaining traction. Most recently, Lipid Nanoparticles (LNP) have been used successfully to construct the SARS-CoV-2 mRNA vaccines for rapid pandemic response. Similarly, silica is another nanomaterial which holds much potential to create nanomedicines against pathogens of interest. One major advantage of silica-based nanoparticles is its crystalline and highly ordered structure, which can be specifically tuned to achieve the desired properties needed for clinical applications. Increasingly, clinical research has shown the potential of silica nanoparticles not only as an antiviral, but also its ability as a delivery system for antiviral small molecules and vaccines against viruses. Silica has an excellen

SUBMITTER: Tng DJH 

PROVIDER: S-EPMC9776486 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature